ARTICLE | Clinical News

VT-1161: Additional Ph IIb REVIVE data

January 13, 2017 7:53 PM UTC

Additional data from the double-blind, U.S. Phase IIb REVIVE trial in 215 patients with recurrent vulvovaginal candidiasis showed that 150 and 300 mg doses of oral VT-1161 once daily for 7 days and th...